Literature DB >> 15496972

Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support.

F E Bertrand1, J D Spengemen, J G Shelton, J A McCubrey.   

Abstract

Bone marrow stromal cells are essential for the differentiation, survival and proliferation of normal and leukemic human B-lineage cells. Leukemic cells require stromal cell support for optimal proliferation and apoptotic resistance. Stromal cell contact can promote resistance to chemotherapeutic agents. In this study, we have made use of small molecular weight inhibitors and an established stromal cell-dependent pre-B-ALL cell line, BLIN-2, to investigate the role of the MAP kinase, PI3K/Akt, JAK/STAT and mTOR pathways in the promotion of leukemic cell growth in the presence of stromal cell support. Treatment with PI3K+JAK, PI3K+MEK, or MEK+JAK inhibitor combinations resulted in an inhibition of proliferation as measured by DNA synthesis. However, only inhibition of both PI3K and MEK or both mTOR and MEK resulted in a dramatic increase in the number of annexinV(+)/PI(+) apoptotic events within a 24 h period. Our data suggest that stromal cell-mediated apoptotic protection in B-lineage ALL is mediated by PI3K/mTOR and MEK via a synergistic mechanism(s).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15496972     DOI: 10.1038/sj.leu.2403560

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice.

Authors:  Sara L Rohrabaugh; Timothy B Campbell; Giao Hangoc; Hal E Broxmeyer
Journal:  Blood Cells Mol Dis       Date:  2011-04-15       Impact factor: 3.039

2.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; Michelle Y Doral; Michael J Borowitz; Brent L Wood; I-Ming Chen; Richard C Harvey; Julie M Gastier-Foster; Cheryl L Willman; Stephen P Hunger; Charles G Mullighan; Mignon L Loh
Journal:  Blood       Date:  2012-06-08       Impact factor: 22.113

3.  Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.

Authors:  Steven M Kornblau; Matthew Womble; Yi Hua Qiu; C Ellen Jackson; Wenjing Chen; Marina Konopleva; Elihu H Estey; Michael Andreeff
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

4.  Tyrosine dephosphorylation is required for Bak activation in apoptosis.

Authors:  Joanna L Fox; Ferina Ismail; Abul Azad; Nicola Ternette; Sabrina Leverrier; Mariola J Edelmann; Benedikt M Kessler; Irene M Leigh; Sarah Jackson; Alan Storey
Journal:  EMBO J       Date:  2010-10-19       Impact factor: 11.598

Review 5.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

6.  Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation.

Authors:  Timothy B Campbell; Sunanda Basu; Giao Hangoc; Wen Tao; Hal E Broxmeyer
Journal:  Blood       Date:  2009-08-18       Impact factor: 22.113

Review 7.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy.

Authors:  A H Nwabo Kamdje; G Bassi; L Pacelli; G Malpeli; E Amati; I Nichele; G Pizzolo; M Krampera
Journal:  Blood Cancer J       Date:  2012-05-25       Impact factor: 11.037

9.  Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).

Authors:  Karolina Nemes; Anna Sebestyén; Agnes Márk; Melinda Hajdu; István Kenessey; Tamás Sticz; Eszter Nagy; Gábor Barna; Zsófia Váradi; Gábor Kovács; László Kopper; Monika Csóka
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

Review 10.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.